Clinical utility of urine pregnancy assays to determine medical abortion outcome is limited

Contraception

Volumn 75, Issue 5, 2007, Pages 378-382

  Godfrey, Emily M ^a   Anderson, Anita ^b   Fielding, Stephen L ^c   Meyn, Leslie ^d   Creinin, Mitchell D ^d,e  

^a UNIVERSITY OF ILLINOIS   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^c UNIVERSITY OF ROCHESTER   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Likelihood ratio; Medical abortion; Mifepristone; Predictive value; Sensitivity; Specificity; Urine pregnancy test

Indexed keywords

MIFEPRISTONE; MISOPROSTOL;

ABORTION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST; ECHOGRAPHY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PREGNANCY; PREGNANCY TEST; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; URINALYSIS;

ABORTION, INDUCED; CHORIONIC GONADOTROPIN; FEMALE; HUMANS; PREGNANCY; PREGNANCY TESTS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 34047255922     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2007.01.021     Document Type: Article

References (23)

1. Strauss L.T., Herndon J., Chang J., Parker W.Y., Bowens S.V., and Berg C.J. Abortion surveillance - United States, 2002. Morb Mortal Wkly Rep Surveill Summ 54 (2005) 1-31
2. Benson J., Clark K.A., Gerhardt A., Randall L., and Dudley S. Early abortion services in the United States: a provider survey. Contraception 67 (2003) 287-294
3. Joffe C. Reactions to medical abortion among providers of surgical abortion: an early snapshot. Fam Plann Perspect 31 (1999) 35-38
4. Creinin M.D., Fox M., Teal S., Chen A., Schaff E., and Meyn L.A. Randomized comparison of misoprostol 6 to 8 hours versus 24 hours after mifepristone for abortion. Obstet Gynecol 103 (2004) 851-859
5. von Hertzen H., Honkanen H., Piaggio G., et al. WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion: I. Efficacy. Br J Obstet Gynecol 110 (2003) 808-818
6. Henderson J.T., Hwang A.C., Harper C.C., and Stewart F.H. Safety of mifepristone abortions in clinical use. [see comment]. Contraception 72 (2005) 175-178
7. Hausknecht R. Mifepristone and misoprostol for early medical abortion: 18 months experience in the United States. Contraception 67 (2003) 463-465
8. Orioli I.M., and Castilla E.E. Epidemiological assessment of misoprostol teratogenicity. Br J Obstet Gynecol 107 (2000) 519-523
9. Gonzalez C.H., Marques-Dias M.J., Kim C.A., et al. Congenital abnormalities in Brazilian children associated with misoprostol misuse in first trimester of pregnancy. [see comment]. Lancet 351 (1998) 1624-1627
10. Coelho K.E., Sarmento M.F., Veiga C.M., et al. Misoprostol embryotoxicity: clinical evaluation of fifteen patients with arthrogryposis. Am J Med Genet 95 (2000) 297-301
11. Schuler L., Pastuszak A., Sanseverino T.V., et al. Pregnancy outcome after exposure to misoprostol in Brazil: a prospective, controlled study. Reprod Toxicol 13 (1999) 147-151
12. Ellertson C., Elul B., and Winikoff B. Can women use medical abortion without medical supervision?. Reprod Health Matters 5 (1997) 149-161
13. Grossman D., Ellertson C., Grimes D.A., and Walker D. Routine follow-up visits after first-trimester induced abortion. Obstet Gynecol 103 (2004) 738-745
14. Acharya G., Haugen M., Brathen A., Nilsen I., and Maltau J.M. Role of routine ultrasonography in monitoring the outcome of medical abortion in a clinical setting. Acta Obstet Gynecol Scand 83 (2004) 390-394
15. Walker K., Schaff E., Fielding S., and Fuller L. Monitoring serum chorionic gonadotropin levels after mifepristone abortion. Contraception 64 (2001) 271-273
16. Creinin M.D. Change in serum beta-human chorionic gonadotropin after abortion with methotrexate and misoprostol. Am J Obstet Gynecol 174 (1996) 776-778
17. Fiala C., Safar P., Bygdeman M., and Gemzell-Danielsson K. Verifying the effectiveness of medical abortion; ultrasound versus hCG testing. Eur J Obstet Gynecol Reprod Biol 109 (2003) 190-195
18. Schaff E.A., Eisinger S.H., Franks P., and Kim S.S. Combined methotrexate and misoprostol for early induced abortion. Arch Fam Med 4 (1995) 774-779
19. Creinin M.D., and Vittinghoff E. Methotrexate and misoprostol vs misoprostol alone for early abortion. A randomized controlled trial. JAMA 272 (1994) 1190-1195
20. van der Lugt B., and Drogendijk A.C. The disappearance of human chorionic gonadotropin from plasma and urine following induced abortion. Disappearance of HCG after induced abortion. Acta Obstet Gynecol Scand 64 (1985) 547-552
21. Harwood B., Meckstroth K.R., Mishell D.R., and Jain J.K. Serum beta-human chorionic gonadotropin levels and endometrial thickness after medical abortion. Contraception 63 (2001) 255-256
22. Creinin M.D., and Spitz I.M. Use of various ultrasonographic criteria to evaluate the efficacy of mifepristone and misoprostol for medical abortion. Am J Obstet Gynecol 181 6 (1999) 1419-1424
23. Rossi B., Creinin M.D., and Meyn L.A. Ability of the clinician and patient to predict the outcome of mifepristone and misoprostol medical abortion. Contraception 70 (2004) 313-317